The investigators described DEFeAT as a single-centre, randomised, double-blinded, placebo-controlled trial enrolling 150 biologically female participants with iron deficiency. Recruitment and follow-up will span six months. Random allocation will assign individuals either to an active intervention arm or to a placebo arm, and blinding will be maintained for participants and study staff. The protocol specifies the primary assessment timepoint at six months for the main outcomes. The source did not present participant demographic breakdowns or inclusion/exclusion criteria in full within the abstract, but the stated population is women of reproductive age diagnosed with iron deficiency.
Authors reported that the active product is a home beverage fortification powder formulated with electrolytic iron and zinc sulphate monohydrate, described as having a small particle size intended to reduce gastrointestinal irritation and enhance bioavailability. The formulation choice aims to use low iron levels to limit side effects while maintaining acceptability. The source, however, did not provide specific dosing amounts, daily administration instructions, exact ingredient concentrations, or details of the placebo powder composition in the publicly available protocol abstract. Those quantitative regimen details are therefore not available from the preprint text.
The trial team designated co-primary outcomes: change in serum ferritin concentrations and the proportion of participants who remain iron deficient at six months. Short, focused endpoints like these track iron stores rather than symptoms alone. Secondary endpoints include longitudinal changes in both serum ferritin and haemoglobin across the scheduled timepoints, levels of selected circulating metabolites and pro-inflammatory biomarkers, and measures of diet and self-reported health. The protocol also builds in pragmatic outcomes: participant-perceived palatability, barriers to use, adherence metrics, and standard safety assessments, plus a cost-effectiveness analysis. The abstract did not enumerate exact laboratory panels, assay methods, or predefined thresholds for endpoint classification beyond the high-level outcome labels.
Investigators plan exploratory profiling of the gut microbial metagenome and the metabolome. These analyses aim to characterise microbial and metabolic responses to home fortification in a subset or the whole cohort; the preprint did not specify sample timing, sequencing platforms, metabolomics methods, or analytical pipelines. The team also indicated assessment of key circulating pro-inflammatory biomarkers, but the abstract omitted the specific biomarkers to be measured and the laboratory techniques to be used.
The protocol lists approvals from the Montfort Hospital Research Ethics Board, Carleton University Research Ethics Board, University of Ottawa Research Ethics Board, and Algonquin College Research Ethics Board. The study has Clinical Trial Application Authorisation from Health Canada's Natural and Nonprescriptive Health Products Directorate under file number 257665 and protocol number LIFe2022RCT2. Trial registration is provided as ClinicalTrials.gov NCT05990166. Funders named in the document include Lucky Iron Life Enterprise, Inc., the National Research Council of Canada Industrial Research Assistance Programme (NRC IRAP), and an innovation development grant from Natural Products Canada. The preprint states that no competing interests were declared by the authors.
This report describes a protocol rather than trial results; no outcome data or participant-level findings are presented. Several operational details are not included in the abstracted text: the exact iron and zinc quantities per dose, daily dosing schedule, placebo composition, laboratory assay specifics, and the statistical power calculation or threshold assumptions beyond the planned sample size of 150. The source did not report whether subgroup analyses or interim analyses are planned, nor did it supply the full statistical analysis plan in the abstract. Those unresolved items will be important to evaluate when the full protocol or trial results are published or posted to the registry. The next concrete administrative milestone listed by the authors is the public ClinicalTrials.gov registration (NCT05990166); additional methodological detail should be sought in the full protocol or registry entry for operational clarity.